MetaVia is trading 17.43% higher at $1.26 on November 6 after positive interim Phase 1 results for DA-1726 announced November 5. - The small study showed a 68% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight reduction after 16 weeks. - The company plans a Phase 2 study in MetALD and ALD. - Broader markets also rose on November 6, adding supportive risk-on context; no trading-volume figure was available.